

Creating a World of Bionic Vision for Those Who Have Lost Their Sight

Forward Looking Statements



This document contains information on Pixium Vision's markets and competitive position, and more specifically, on the size of its potential markets. This information has been drawn from various sources or from the companies own estimates. Investors should not base their investment decision on this information. This document also contains certain forward-looking statements. These statements are not a guarantee of the Company's future performance. These forward-looking statements relate to the Company's future prospects, developments and marketing strategy and are based on analyses of earnings forecasts and estimates of amounts not yet determinable. Forward-looking statements are subject to a variety of risks and uncertainties as they relate to future events and are dependent on circumstances that may or may not materialize in the future. Pixium Vision draws your attention to the fact that as forward-looking statements cannot under any circumstance be construed as a guarantee of the Company's future performance and that the Company's actual financial position, results and cash flow, as well as the trends in the sector in which the Company operate may differ materially from those proposed or reflected in the forward-looking statements contained in this document. Furthermore, even if Pixium Vision's financial position, results, cash-flows and developments in the sector in which the Company operates were to conform to the forward-looking statements contained in this document, such results or developments cannot be construed as a reliable indication of the Company's future results or developments. The Company does not undertake any obligation to update or to confirm projections or estimates made by analysts or to make public any correction to any prospective information in order to reflect an event or circumstance that may occur after the date of this presentation. A description of those events that may have a material adverse effect on the business, financial position or results of Pixium Vision, or on its ability to meet its targets, appears in the sections "Risk Factors" of its "Document de Base" filed with the French Autorité des Marchés Financiers. By attending this presentation or accepting this document, you agree to be bound by the foregoing restrictions set out above.

Pixium Creates a World of Bionic Vision for Those Who Have Lost Their Sight





A tiny wireless neurostimulating retina implant and smartglasses capable of communicating with implant generating bionic vision for blind and partially blind patients





...to **create** meaningful **sight** and **regain** independence...

To give back meaningful vision and independence to patients suffering from Dry AMD and other retinal diseases that currently have no other solution



...and lead by a **seasoned team** which combines >100 years experience in Medtech




























...by **finalizing clinical trials** and commercialization of the PRIMA system...

Leveraging Pixium's cutting edge know-how created to finalize the pivotal PRIMAvera trial in the EU and lead the PRIMA system to market approvals in US, EU and other countries.

Creating a World of Bionic Vision for Those Who Have Lost Their Sight





Breakthrough Technology

De-risked state of the art ophthalmic neuromodulation technology



Results exceeding expectations with up to 36month follow-up data with 5 patients in Dry AMD demonstrating the ability for clinically blind patients to read letters and words



Large Markets

245k visually impaired Dry AMD patients leading to a €19b market opportunity in the US and EU5 combined



Clear Way to Market

Expected to be 1st to commercialize due to advanced clinical progress and to become the only treatment option



Reimbursement

Expect average €80,000 generated per patient




Top Tier Teams

Experienced management supported by top-tier KOL group

Delivering on our Journey and Approaching the Next Chapter of Pixium and the Prima System





Experienced Management Team with Over 100 years in Medtech











Lloyd DiamondChief Executive
Officer







Offer Nonhoff
Chief Financial
Officer











Guillaume Buc Chief Technology Officer





Ralf Hornig, PhD
Director Clinical
Affairs



Marine Chevrie, PhD
Director Regulatory

Director Regulatory Chief Medical Advisor
Affairs and Quality








Lisa Omos de Koo, MD





Creating a World of Bionic Vision for Those Who Have Lost Their Sight









[&]quot;...Simultaneous use of the prosthetic central vision and the natural peripheral vision in both the implanted eye and the fellow eye is a very important feature of the Prima System for patients with geographic atrophy and is essential for improving their quality of life,..."

Prima System Delivering Encouraging Results for Patients











AMD

Age Related Macular Degeneration

Dry AMD Is More Common And Can Be As Equally Debilitating As Well Treated Wet AMD




- Chronic progressive neurodegenerative eye disease leading to loss of central vision due to a degeneration of photoreceptor cells in the Retina
- Dry AMD may first develop in one or both eyes and then affects both eyes
- **Dry AMD 80% 90% / Wet AMD 10% 20%.** Dry AMD may progress to wet AMD, which can cause rapid vision loss if left untreated.
- Onset mostly around 60 years old
- Significant impact on quality of life, impeding ability to read, use transportation, social interactions, and other daily tasks
- Loss of quality of life for advanced AMD patients is comparable to dialysis, advanced prostate cancer or severe stroke¹
- There is currently **no** approved **treatment** for sight restoration for Dry-AMD
- We believe Pixium's Prima System can become 1st approved Dry-AMD treatment

Total AMD population US and EU5²

63.9_m

Degeneration of Photoreceptor Cells while Optic Nerve stays intact






Significant Impact on Patients' and Their Surrounding



Dry AMD is amongst the most debilitating disease for patients leading to:

- Significant psychological impact
- Societal impact through high degree of dependency




Main Targets of Prima System

An Extremely Large, Fast Growing and Untapped Dry AMD Market



Based on 2022 epidemiological data growing about 10% until 2028

(1) GlobalData Age Related Macular Degeneration Epidemiology Forecast 21.Dec.2021



Total Current Accessible Market

€ 19.6b € 12.2 € 7.3

Market Size based on Incidence of 22,300
Patients per Year

€ 1.6b = €0

Expanding indications to Retinitis Pigmentosa will increase market materially



[&]quot;...The Prima System has the potential to significantly improve vision and quality of life for patients with dry AMD and I am looking forward to bringing it to more patients in need..."



The Prima System

The Prima System



An Innovative Combination of an Implant and Smart Glasses


Implant

Interface to the Optic Nerve



Smart Glasses

Camera, Projector, Computer, cutting edge Artificial Intelligence





Implant



Cutting-edge Image Processing System



Minimally Invasive Implantation and Optimized Patient Training




High Precision Optics and Projection



Versatile and Upgradeable

State of the Art Implant





Partially replaces Exclusive function of central Stanford collaboration photoreceptor cells University with Stanford while leaving peripheral University vision unaltered 378 electrodes in a Fully wireless, 2x2mm module activated using thinner than a high-precision human hair projection system **Implant** durability tested No battery in-vitro for 10+ vears **Surgeon friendly Patent protected** high-precision design and implant delivery manufacturing device process



Dr. Yannick Le MerHead of Vitreo-retinal Unit
Fondation Adolphe de Rothschild
(Paris, France)


[&]quot;...the implant is shown to be reliable in patients for over 36 months post implantation. These encouraging results position Pixium's PRIMA implant, and the whole Prima System, as a realistic potential solution.."

Glasses and Pocket Computer



MINIATURIZED CAMERA

Captures the patient visual environment and transmits the data to the image processing stem



PROPRIETARY ALGORITHMS

Analyses the image stream, simplifies the contents to highlight a specific area and transforms the result into the signal to be projected on the implant

TRANSPARENT GLASSES

Regular-looking glasses with tunable projection module allowing to combine bionic vision and peripheral vision




SOPHISTICATED PROJECTION

Transfers electronic signals of images to activate safely the implant electrodes with high precision

"...The bionic vision Prima System has demonstrated improved vison function and could potentially make a significant impact to patients' quality of life.."

A Potential Solution for Vision Restoration





Link to video PRIMA System operating principle on Vimeo

Prima Technology



Developed with Patients and Physicians in Mind

Wireless Neurostimulation Implant

Cutting-edge Image Processing System

High Precision Optics and Projection

Easily Implantable and Optimized Patient Training

Versatile and Upgradeable



PRIMA is a tiny neurostimulation device implantable in the subretinal space



Dedicated imaging processor with proprietary algorithm optimized to characteristics of bionic vision, to limit latency and maximize reactivity



Allows to precisely activate implant and to transfer visual content with low latency and hyper-short on-off timing



Minimally invasive surgery through a patented implant delivery device – doable by most EU/US retinal surgeons; patient's training optimized to allow independence




Potential addition of life-easing technologies on external components side such as stimulation algorithmics improvement, 5G connectivity, road mapping and direction with VR capabilities

Surgery & Rehabilitation



Process










Low vision specialists train use of device, basic shapes, reading, orientation and other daily living tasks for 3 months






Remote Rehab and Gamification Hub



New Scalable Platform and First Step Towards Face Recognition



21



The above picture is for illustration purpose only

* Version in clinical trials



Clinical Data






Dry AMD

	Feasibility Study	Regulatory Pathway	Pivotal Study	Regulatory Submission
****	Follow-up 6, 12, 18, 24 and 36 month showing meaningful reading continuing until 72 month	Approved	V E R A Ongoing Readout end 2023	Expected early 2024
	Ongoing Read out H2 2023	Ongoing discussion with FDA	Expected Start 2024	Expected 2026



Encouraging Results in European First-In-Human Study

PRIMA has the potential to meaningfully restore central vision



^{1 –} France first-in-human study (PRIMA FS) recruited 5 patients. Primary endpoint is Elicitation of visual perception at 18 months with up to 36-month follow-up





Actively enrolling in 17 centers



38 Dry-AMD **patients** to be recruited



Primary endpoint:

Visual Acuity (ETDRS)



12 months follow up for primary endpoints (further endpoints @ 36 months)

2021	2022	2023		2024	
	Follow up	Data	C€	Approval	



Publications

nature biomedical engineering

About the journal Publish with us

Explore content V nature > nature biomedical engineering > articles > article

Behavioural responses to a photovoltaic subretinal prosthesis implanted in non-human primates

Paul-Henri Prévot, Kevin Gehere, Lul Serge Picaud

Nature Biomedical Engineering 4, 172-180 (2020) | Cite th

1669 Accesses | 19 Citations | 47 Altmetric | Metrics

Retinal dystrophies and age-related macular deger Abstract blindness. In blind patients, although the electrical



Photovoltaic Restoration of Central Vision in Atrophic Age-Related Macular Degeneration

Search Q Login (2)

Daniel Palanker, PhD, Yannick Le Mer, MD, Saddek Mohand-Said, MD, 37 Mahind Muait, PhD, FRCOthih, 4,5 Jose A, Sahel, MD, 3,6

nature communications About the journal > Publish with us >

Jose A. Sahel, MD^{2,3}, Purpose: Loss of photoreceptors in atrophic impaiment, although some peripheral vision is ri

View all journals

residual peripheral field, we developed a wireles France) in which pixels convert images projected fr to stimulate the nearby inner retinal neurons. Design: We carried out a first-in-human clinic

tients with geographic atrophy (Clinical Trials.gov it Participants: Five patients with geographic at perception, and best-corrected visual acuity of 20 Methods: The 2-mm wide, 30-um thick chip, o subretinally in the area of atrophy (absolute scotor

Main Outcome Measures: Anatomic outcome 12 months of follow-up. Prosthetic vision was at

recognition, and Landolt C acuity.

Results: In all patients, the prosthesis was imp was implanted in unintended locations; within the white-yellow prosthetic visual patterns with adjusta placement of the implant demonstrated prosthetic implant demonstrated 20/800 acuity. Residual nati

Conclusions: Implantation of the PRIMA did n sensitivity in the former scotoma in each of the 5 year or electronic magnifica

Explore content ~

nature > nature communications > articles > article

Simultaneous perception of prosthetic and natural Article | Open Access | Published: 26 January 2022

vision in AMD patients

D. Palanker , Y. Le Mer, S. Mohand-Said & J. A. Sahel

Nature Communications 13, Article number: 513 (2022) | Cite this article

1644 Accesses | 34 Altmetric | Metrics



(AND) results in seven




Conclusion

Prima System



Cutting-Edge Technology Supported by Multi-disciplinary Partners























Prof. Jose-Alain Sahel

Vision Institute (FR) UPMC (Pittsburgh, US)



University Hospital Bonn (DE)

Prof. Daniel Palanker

Stanford University (US)

Dr. Yannick Le Mer

Fondation Adolphe de Rothschild (FR)

Prof. Borja Corcostegui

IMO, Institute of Ocular Microsurgery (ES)

Dr. Mahi Muqit

Moorfield Eye Hospital (UK)

Prof. Andrea Cusumano

University of Rome (IT)

Prof. Jan Van Meurs

Rotterdam Eye Hospital (NL)





















Leveraging Solid Foundations to Deliver on our Promises



State of the art technology platform to address most common and debilitating ophthalmic condition in 60+ year old patients



Ongoing PRIMAvera European Pivotal study with read-out expected end 2023, potential EU approval expected in late 2024 – Followed by potential US approval



Initial target of \$ 1.6bn incidence market followed by progressive penetration of \$ 19bn prevalence market Business model expandable through technological upgrades and additional services/maintenance



Wide and robust intellectual property and know-how to support long-term market leadership



Strengthening presence in key strategic US market

10 years of technological refinement to deliver a potential solution in the next 2-4 years

Thank you

Lloyd Diamond, CEO | E: ldiamond@pixium-vision.com



